Clinical significance of soluble Fas plasma levels in patients with sepsis
Abstract
Background/Aim. The goal of modern clinical and experimental researches in the field of sepsis is to find one or more sensitive parameters that could predict the severity of sepsis and its outcome. In this study we investigated and compared the relationship of initial soluble Fas (sFas) plasma levels as well as Acute Physiology, Age and Chronic Health Evaluation II (APACHE II) score in 58 septic patients with severity and outcome of sepsis. Methods. The diagnosis and assessment of disease severity was performed on the same day, based on clinical and laboratory parameters. The blood samples were used for monitoring of laboratory standard parameters necessary for the diagnosis of sepsis, organ dysfunction and assessment of disease severity, as well as for determination of levels of sFas. According to consensus criteria, patients were divided into those with sepsis (n = 16), severe sepsis (n = 30) or septic shock (n = 12), those with (n = 26) and without (n = 32) multiple organ dysfunction syndrome (MODS), and survivors (n = 45) and non-survivors (n = 13). Results. Plasma sFas level (9.7 ± 10.1; 0–44.2 U/mL) was elevated in 54.4% of patients. All the patients with septic shock, 76.9% of the patients with MODS and 84.6% patients who died had elevated sFas level. We observed a strong positive correlation between sFas and APACHE II score (p < 0.001). The level of sFas was significantly higher in patients with septic shock compared to normotensive patients (p < 0.001), patients with MODS compared to those without MODS (p < 0.001) and survivors compared to nonsurvivors (p < 0.01). Conclusions. Our results suggest that initial sFas plasma levels in patients with sepsis correlated with the values of APACHE II score and separated very well the patients with septic shock versus the normotensive patients, the patients with and without MODS, and survivors versus non-survivors
References
Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013; 369(9): 840−51.
Martin GS. Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. Expert Rev Anti Infect Ther 2012; 10(6): 701−6.
Gustot T. Multiple organ failure in sepsis: prognosis and role of systemic inflammatory response. Curr Opin Crit Care 2011; 17(2): 153−9.
Kaukonen K, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill pa-tients in Australia and New Zealand, 2000-2012. JAMA 2014; 311(13): 1308−16.
Shapiro NI, Trzeciak S, Hollander JE, Birkhahn R, Otero R, Osborn TM, et al. A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Crit Care Med 2009; 37(1): 96−104.
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 2012; 41(2): 580−637.
Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D, et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a pro-pensity-matched analysis. Crit Care Med 2010; 38(9): 1773−85.
Mikic D, Andrejevic T . The monograph - Proinflammatory cy-tokines in sepsis and septic shock. Belgrade: Zadužbina An-drejević; 2003. (Serbian)
Mikic D, Vasilijic S, Maravic V, Colic M. Relationship between plasma levels of procalcitonin, tumor necrosis factor-α and C-reactive protein and clinical characteristic of septic patients. Clin Appl Immunol 2006; 5(1): 556−62.
Abello PA, Fidler SA, Bulkley GB, Buchman TG. Antioxidants modulate induction of programmed endothelial cell death (apoptosis) by endotoxin. Arch Surg 1994 129(2): 134−40.
Ayala A, Herdon CD, Lehman DL, Ayala CA, Chaudry IH. Dif-ferential induction of apoptosis in lymphoid tissues during sepsis: variation in onset, frequency, and the nature of the me-diators. Blood 1996; 87(10): 4261−75.
Savill J. Apoptosis in resolution of inflammation. J Leukoc Biol 1997; 61(4): 375−80.
Oberholzer C, Oberholzer A, Clare-Salzler M, Moldawer LL. Apop-tosis in sepsis: a new target for therapeutic exploration. FASEB J 2001; 15(6): 879−92.
Marshall JC, Watson RW. Apoptosis in the resolution of sys-temic inflammation. In: Vincent JI. , editor. Yearbook of in-tensive care and emergency medicine. New York: Springer; 1997. p. 100−8.
van Parijs L, Abbas AK. Role of Fas-mediated cell death in the regulation of immune responses. Curr Opin Immunol 1996; 8(3): 355−61.
Abbas AK, Lichtman AH, Pober JS. Apoptosis in lymphocytes. In: Abbas AK, Lichtman AH, Pober JS, editors. Cellular and molecular immunology. 4th ed. Philadelphia, Pensilvania: WB Saunders Company; 2000. p. 220−2.
Ayala A, Chung CS, Xu YX, Evans TA, Redmond KM, Chaudry IH. Increased inducible apoptosis in CD4+ T lymphocytes during polymicrobial sepsis is mediated by Fas ligand and not endotoxin. Immunology 1999; 97(1): 45−55.
Ayala A, Xu YX, Chung CS, Chaudry IH. Does Fas ligand or endotoxin contribute to thymic apoptosis during polymicrobial sepsis. Shock 1999; 11(3): 211−7.
Ayala A, Xin XY, Ayala CA, Sonefeld DE, Karr SM, Evans TA, et al. Increased mucosal B-lymphocyte apoptosis during polymicrobial sepsis is a Fas ligand but not an endotoxin-mediated process. Blood 1998; 91(4): 1362−72.
Ayala A, Chung CS, Song GY, Chaudry IH. IL-10 mediation of activation-induced TH1 cell apoptosis and lymphoid dysfunc-tion in polymicrobial sepsis. Cytokine 2001; 14(1): 37−48.
Fanning NF, Kell MR, Shorten GD, Kirwan WO, Bouchier-Hayes D, Cotter TG, et al. Circulating granulocyte macrophage colony-stimulating factor in plasma of patients with the systemic in-flammatory response syndrome delays neutrophil apoptosis through inhibition of spontaneous reactive oxygen species generation. Shock 1999; 11(3): 167−74.
Matute-Bello G, Liles WC, Radella F, Steinberg KP, Ruzinski JT, Hudson LD, et al. Modulation of neutrophil apoptosis by gran-ulocyte colony-stimulating factor and granulocyte/macrophage colony-stimulating factor during the course of acute respirato-ry distress syndrome. Crit Care Med 2000; 28(1): 1−7.
Paunel-Görgülü A, Flohé S, Scholz M, Windolf J, Lögters T. In-creased serum soluble Fas after major trauma is associated with delayed neutrophil apoptosis and development of sepsis. Critical Care 2011; 15(1): 20.
Wesche DE, Lomas-Neira JL, Perl M, Chung C, Ayala A. Leuko-cyte apoptosis and its significance in sepsis and shock. J Leu-koc Biol 2005; 78(2): 325−37.
Brown KA, Brain SD, Pearson JD, Edgeworth JD, Lewis SM, Treacher DF. Neutrophils in development of multiple organ failure in sepsis. Lancet 2006; 368(9530): 157−69.
Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, et al. Apoptotic cell death in patients with sep-sis, shock, and multiple organ dysfunction. Crit Care Med 1999; 27(7): 1230−51.
Papathanassoglou ED, Moynihan JA, Ackerman MH. Does pro-grammed cell death (apoptosis) play a role in the development of multiple organ dysfunction in critically ill patients? a review and a theoretical framework. Crit Care Med 2000; 28(2): 537−49.
Zeerleder S, Zwart B, Wuilleman WA, Aarden LA, Groeneveld AB, Calisz C, et al. Apoptosis in Sepsis and Multiple Organ Dys-function Syndrome. Advanc Crit Care Test 2004; p. 3−13.
Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263(5154): 1759−62.
Fleck M, Reng M, Mountz JD. Significantly elevated levels of soluble Fas (CD95/Apo-1) in sera of septic shock. Shock 2000; 13: A457.
Papathanassoglou ED, Moynihan JA, McDermott MP, Ackerman MH. Expression of Fas (CD95) and Fas ligand on peripheral blood mononuclear cells in critical illness and association with multiorgan dysfunction severity and survival. Crit Care Med 2001; 29(4): 709−18.
Endo S, Inada K, Takakuwa T, Kasai T, Yamada Y, Wakabayashi G, et al. Nitrite/nitrate (NOx) and sFas antigen levels in pa-tients with multiple organ failure. Res Commun Mol Pathol Pharmacol 1996; 92(2): 253−6.
Papathanassoglou ED, Moynihan JA, Vermillion DL, McDermott MP, Ackerman MH. Soluble fas levels correlate with multiple organ dysfunction severity, survival and nitrate levels, but not with cellular apoptotic markers in critically ill patients. Shock 2000; 14(2): 107−12.
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101(6): 1644−55.
Vincent JL, Moreno R, Takala J, Willatts S, de Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22(7): 707−10.
Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13(10): 818−29.
Yasuda N, Gotoh K, Minatoguchi S, Asano K, Nishigaki K, Nnomura M, et al. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. Respir Med 1998; 92(8): 993−9.
De Freitas I, Fernández-Somoza M, Essenfeld-Sekler E, Cardier JE. Serum levels of the apoptosis-associated molecules, tumor ne-crosis factor-alpha/tumor necrosis factor type-I receptor and Fas/FasL, in sepsis. Chest 2004; 125(6): 2238−46.
Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are pro-duced by alternative splicing. J Immunol 1995; 154(6): 2706−13.
Siegel RM, Chan FK, Chun HJ, Lenardo MJ. The multifaceted role of Fas signaling in immune cell homeostasis and autoim-munity. Nat Immunol 2000; 1(6): 469−74.
Park DR, Thomsen AR, Frevert CW, Pham U, Skerrett SJ, Kiener PA, et al. Fas (CD95) induces proinflammatory cytokine re-sponses by human monocytes and monocyte-derived macro-phages. J Immunol 2003; 170(12): 6209−16.
Huttunen R, Syrjänen J, Vuento R, Laine J, Hurme M, Aittoniemi J. Apoptosis markers soluble Fas (sFas), Fas Ligand (FasL) and sFas/FasL ratio in patients with bacteremia: a prospective co-hort study. J Infect 2012; 64(3): 276−81.
Silvestris F, Grinello D, Tucci M, Cafforio P, Dammacco F. En-hancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-I) in active lupus. Lupus 2003; 12(1): 8−14.
Ma Y, Ye F, Lv W, Cheng Q, Chen H, Xie X. Correlation between soluble Fas level and apoptosis of T cells in ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 2008; 138(2): 204−11.
Papathanassoglou ED, Movnihan JA, Dafni O, Mantzoros CS, Ackerman MH. Association of proinflammatory molecules with apoptotic markers and survival in critically ill multiple organ dysfunction patients. Biol Res Nurs 2003; 5(2): 129−41.
Clark MA, Plank LD, Connolly AB, Streat SJ, Hill AA, Gupta R, et al. Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis--a randomized, clinical trial. Crit Care Med 1998; 26(10): 1650−9.
Torre D, Tambini R, Manfredi M, Mangani V, Livi P, Maldifassi V, et al. Circulating levels of FAS/APO-1 in patients with the sys-temic inflammatory response syndrome. Diagn Microbiol In-fect Dis 2003; 45(4): 233−6.
Hashimoto S, Kobayashi A, Kooguchi K, Kitamura Y, Onodera H, Nakajima H. Upregulation of two death pathways of perfor-in/granzyme and FasL/Fas in septic acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161(1): 237−43.
Keel M, Ungethüm U, Steckholzer U, Niederer E, Hartung T, Trentz O, et al. Interleukin-10 counterregulates proinflammatory cy-tokine-induced inhibition of neutrophil apoptosis during se-vere sepsis. Blood 1997; 90(9): 3356−63.